RxDoctor Payments Data

Ron Guevara, DO

Family Medicine · Robstown, TXNPI 1811967300

Payments from drug & device makers

$548in general payments, 2019–2025

Across 27 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$180
  • Lilly USA, LLC$82
  • Teva Pharmaceuticals USA, Inc.$51
  • AstraZeneca$44
  • Boehringer Ingelheim$36
  • Merck$34
  • plus $122 from 6 others

What the payments were for

  • Food & beverage$51794%
  • Education$316%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$548 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$397,185
Medicare patients
259
Services billed
9,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$46,811
OzempicSemaglutide38$39,492
EliquisApixaban18$23,031
XareltoRivaroxaban11$18,695
MyrbetriqMirabegron15$11,131
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,445
JanumetSitagliptin Phos/Metformin Hcl12$6,992
SymbicortBudesonide/Formoterol Fumarate15$4,983
Levothyroxine Sodium196$2,269
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,897
BreynaBudesonide/Formoterol Fumarate11$1,887
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,747
Metoprolol Succinate98$1,527
Lisinopril175$1,218
Solifenacin Succinate27$1,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$36$46,81150 claims
Novo NordiskOzempic$180$39,49238 claims
PfizerEliquis$12$23,03118 claims
Johnson & JohnsonXarelto$19$18,69511 claims
Astellas Pharma US IncMyrbetriq$26$11,13115 claims
MerckJanumet$34$6,99212 claims
AstraZenecaSymbicort$44$4,98315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Robstown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →